Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
-NHF and Community News
 Industry News
 Travel Advisory

 

 

 
New MASAC Recommendation Addresses Treatment
 

The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) approved a new treatment recommendation on October 29, 2005, which was subsequently adopted by the NHF Board of Directors on October 30th.

Document #165: MASAC Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders provides an overview of treatment options for physicians who care for patients with hemophilia, von Willebrand disease (VWD) and other bleeding disorders in the U.S. In addition, document #165 includes several tables that list all products available to treat hemophilia A and B, VWD, patients with inhibitors to factor VIII and IX and those with rare factor deficiencies. To view the document go to: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=433

To request a copy of the new recommendation contact HANDI at 800-424-2634 (option two) or handi@hemophilia.org.